Minerva gastroenterology
Cure8 research brief
Why This Matters
A commonly used probiotic, E.
coli Nissle 1917, was associated with short-term increases in gut microbiota diversity and changes in bacterial groups in a small study of people with ulcerative colitis, plus an improvement on a lab intestinal-permeability test—findings that may interest patients and clinicians exploring microbiome-directed approaches.
Who Should Pay Attention
Adults with ulcerative colitis, gastroenterologists, researchers focused on the microbiome or probiotic treatments.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This abstract reports a small clinical study testing the probiotic Escherichia coli Nissle 1917 (EcN) given daily for 30 days to five patients with stable ulcerative colitis.
Stool samples were compared before treatment, after 10 days, and after one month to look at microbiota diversity and taxonomic changes, and a cell-culture assay was used to assess intestinal permeability.
The authors report increased gut microbiota alpha diversity over the treatment period and changes in the relative abundance of multiple bacterial groups at different taxonomic levels. They also report that EcN improved intestinal permeability in an in vitro CaCO2 monolayer assay. These findings are described at the abstract level in this journal record.
This is a small, short-duration study (n=5) reported as an abstract; it suggests EcN may alter microbiota composition and affect a laboratory measure of barrier function, but it does not establish clinical benefits such as symptom improvement or safety in larger populations.
If you are considering probiotics as part of IBD care, discuss them with your gastroenterologist, who can advise based on your disease activity, medications, and the evidence base.
Keep In Mind
Small sample size (n=5) and short treatment duration; results are from an abstract-level journal record and include laboratory permeability testing rather than clinical outcomes.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationMinerva gastroenterology
AuthorsPierluigi Puca, Federica Del Chierico, Cristina Graziani +12 more
InstitutionIBD Unit, CEMAD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy - pgpuca@gmail.com.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 3, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Development of double emulsions loaded with Malus baccata (Linn.) polyphenols and their protective effect on dextran sulfate sodium-induced ulcerative colitis in mice.
Researchers are exploring plant polyphenols and new oral delivery systems that might reduce gut inflammation and modify microbiota — findings in mice suggest potential but are not directly applicable to patients yet.
Synergistic Effect of VSL#3TM and Vedolizumab for Ulcerative colitis: Preliminary Evidence from a Real-world Single-Arm study
The report suggests a probiotic (VSL#3TM) added to vedolizumab may speed or increase early response in ulcerative colitis, which could interest patients and clinicians seeking ways to improve biologic induction outcomes....
Insights into the mechanism of treatment of ulcerative colitis with pre- and post-processed dried ginger through perspective of metabolomics and intestinal microbiomics research.
The study maps how two ginger preparations differently affect metabolism and the gut microbiome in a mouse model of ulcerative colitis, which could inform more targeted use of ginger-derived treatments if findings are...